PROTAC K-Ras Degrader-1 is primarily used in cancer research to target and degrade the K-Ras protein, which is often mutated in various cancers. Its application lies in its ability to selectively bind to K-Ras and recruit an E3 ubiquitin ligase, leading to the protein's ubiquitination and subsequent degradation by the proteasome. This approach is particularly valuable in studying K-Ras-driven cancers, such as pancreatic, lung, and colorectal cancers, where traditional inhibitors have shown limited efficacy. By degrading K-Ras, it offers a potential therapeutic strategy to inhibit oncogenic signaling pathways and suppress tumor growth. Additionally, it serves as a tool for understanding the role of K-Ras in cellular processes and drug resistance mechanisms.